- Botanix Pharmaceuticals (BOT) appoints Dr Howie McKibbon as its newest CEO
- Dr McKibbon was previously Chief Operating Officer at the company
- He has more than 25 years of experience in the pharmaceutical industry and has led the launch of more than 15 products
- FDA approval for Sofpironium Bromide is aimed for the end of September
- Botanix shares last traded at 18.5 cents
Botanix Pharmaceuticals (BOT) has appointed Dr Howie McKibbon as its newest Chief Executive Officer, effective from August 24.
Having also served as the Chief Operating Officer for the company in the past, his more than 25-year background in the pharmaceutical sector was deemed the driving force behind this decision.
Before his involvement with Botanix, Dr McKibbon played pivotal roles in the transformation of dermatology-focused companies.
At Dermavant Sciences, he led the transition of the company from a subsidiary to an independent dermatology entity, while overseeing the acquisition of a flagship product.
“I have had the pleasure of working with Howie in three different dermatology companies before Botanix and I can think of no one better qualified or capable to lead us through this next stage of the company’s growth,” Botanix Executive Chair Vince Ippolito said.
The company is aiming for FDA approval of Sofpironium Bromide at the end of September.
Dr McKibbon will be given an annual remuneration of US$400,000.
Botanix shares last traded at 18.5 cents.